Literature DB >> 20383640

Treatment and outcome in muscle invasive bladder cancer: a population-based survey.

Anna M Leliveld1, Benjamin H J Doornweerd, Esther Bastiaannet, Michael Schaapveld, Igle J de Jong.   

Abstract

OBJECTIVE: To assess treatments and survival of patients with muscle invasive bladder cancer (MIBC) in the Comprehensive Cancer Center Northern Netherlands (CCCN) region. STUDY DESIGN AND
SETTING: Retrospective cohort analysis. Data of 548 patients with MIBC diagnosed between 1997 and 2002 were collected from the CCCN cancer registry. All had a follow-up of at least 5 years. Logistic regression analysis on treatments as well as survival analysis was performed.
RESULTS: The treatments were radical cystectomy in 205/548 (37.5%) patients. TUR plus radiotherapy in 246 (44.9%) and palliation in 97 (17.7%). Multivariate analysis identified TNM stage (P < 0.0001) and age (P < 0.0001) as independent variables for cystectomy. Hospital type and year of diagnosis were not significant different between patients treated by cystectomy versus other type of treatment. TNM stage (P < 0.0001), age (P = 0.0043), and comorbidity (P = 0.0028) were independent variables for disease-specific survival (DSS) after cystectomy.
CONCLUSION: In the CCCN region, only 1/3 of patients with MIBC were treated with radical cystectomy. TNM stage and age were identified as main variables for the choice for cystectomy. TNM stage, age, and comorbidity were independent variables for disease-specific survival after cystectomy.

Entities:  

Mesh:

Year:  2010        PMID: 20383640     DOI: 10.1007/s00345-010-0546-2

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  25 in total

Review 1.  Lymphadenectomy with cystectomy: is it necessary and what is its extent?

Authors:  Mohamed A Ghoneim; Hassan Abol-Enein
Journal:  Eur Urol       Date:  2004-10       Impact factor: 20.096

2.  Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy.

Authors:  R D Mills; W H Turner; A Fleischmann; R Markwalder; G N Thalmann; U E Studer
Journal:  J Urol       Date:  2001-07       Impact factor: 7.450

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

4.  Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study.

Authors:  George R Prout; Margaret N Wesley; Rosemary Yancik; Lynn A G Ries; Richard J Havlik; Brenda K Edwards
Journal:  Cancer       Date:  2005-10-15       Impact factor: 6.860

5.  Four years experience in bladder preserving management for muscle invasive bladder cancer.

Authors:  Michele Lodde; Salvatore Palermo; Evi Comploj; Diego Signorello; Christine Mian; Lukas Lusuardi; Elena Longhi; Peter Zanon; Michael Mian; Armin Pycha
Journal:  Eur Urol       Date:  2005-02-10       Impact factor: 20.096

6.  Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.

Authors:  Pierre I Karakiewicz; Shahrokh F Shariat; Ganesh S Palapattu; Amiel E Gilad; Yair Lotan; Craig G Rogers; Amnon Vazina; Amit Gupta; Patrick J Bastian; Paul Perrotte; Arthur I Sagalowsky; Mark Schoenberg; Seth P Lerner
Journal:  J Urol       Date:  2006-10       Impact factor: 7.450

7.  Gender differences in stage-adjusted bladder cancer survival.

Authors:  N A Mungan; K K Aben; M P Schoenberg; O Visser; J W Coebergh; J A Witjes; L A Kiemeney
Journal:  Urology       Date:  2000-06       Impact factor: 2.649

8.  Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients.

Authors:  Peter E Clark; John P Stein; Susan G Groshen; Jie Cai; Gus Miranda; Gary Lieskovsky; Donald G Skinner
Journal:  Cancer       Date:  2005-07-01       Impact factor: 6.860

9.  Surgical outcomes for patients aged 80 and older: morbidity and mortality from major noncardiac surgery.

Authors:  Mary Beth Hamel; William G Henderson; Shukri F Khuri; Jennifer Daley
Journal:  J Am Geriatr Soc       Date:  2005-03       Impact factor: 5.562

10.  Brachytherapy versus cystectomy in solitary bladder cancer: a case control, multicentre, East-Netherlands study.

Authors:  Elzbieta van der Steen-Banasik; Martine Ploeg; Johannes A Witjes; Farida S van Rey; Jan G Idema; Robert P Heijbroek; Herbert F Karthaus; Janny G Reinders; A Viddeleer; Andries G Visser
Journal:  Radiother Oncol       Date:  2009-05-18       Impact factor: 6.280

View more
  5 in total

1.  Gender-dependent cancer-specific survival following radical cystectomy.

Authors:  Matthias May; Christian Stief; Sabine Brookman-May; Wolfgang Otto; Christian Gilfrich; Jan Roigas; Mario Zacharias; Wolf F Wieland; Hans-Martin Fritsche; Ferdinand Hofstädter; Maximilian Burger
Journal:  World J Urol       Date:  2011-10-09       Impact factor: 4.226

2.  A four-gene signature predicts disease progression in muscle invasive bladder cancer.

Authors:  Wun-Jae Kim; Seon-Kyu Kim; Pildu Jeong; Seok-Joong Yun; In-Chang Cho; Isaac Yi Kim; Sung-Kwon Moon; Hong-Duck Um; Yung Hyun Choi
Journal:  Mol Med       Date:  2011-02-04       Impact factor: 6.354

3.  Bladder preservation by concurrent chemoradiation for muscle-invasive bladder cancer: Applicability in low-income countries.

Authors:  Jamal Khader; Naim Farah; Ahmed Salem
Journal:  Rep Pract Oncol Radiother       Date:  2011-05-23

4.  Development and External Validation of a Novel 12-Gene Signature for Prediction of Overall Survival in Muscle-Invasive Bladder Cancer.

Authors:  MierXiati Abudurexiti; Huyang Xie; Zhongwei Jia; Yiping Zhu; Yao Zhu; Guohai Shi; Hailiang Zhang; Bo Dai; Fangning Wan; Yijun Shen; Dingwei Ye
Journal:  Front Oncol       Date:  2019-09-06       Impact factor: 6.244

5.  Impact of salvage cytotoxic chemotherapy on prognosis in patients with recurrence after radical cystectomy: a multi-institutional retrospective study.

Authors:  Dai Koguchi; Kazumasa Matsumoto; Masaomi Ikeda; Yoshinori Taoka; Takahiro Hirayama; Yasukiyo Murakami; Takuji Utsunomiya; Daisuke Matsuda; Norihiko Okuno; Akira Irie; Masatsugu Iwamura
Journal:  BMC Urol       Date:  2022-05-13       Impact factor: 2.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.